Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo

    NEXT STORY
    Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019
    PREV STORY
    MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

    author_avatar
    NASDAQ Market News

    Loxo Oncology to Announce Fourth Quarter and Year-End 2017 Financial Results

    STAMFORD, Conn., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Motif Bio to Present Iclaprim Data at ECCMID 2019

    author_avatar
    NASDAQ Market News